ImmunityBio vs Immunocore
IBRX and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IBRX and IMCR compare
ImmunityBio is the larger company, worth 5.6 times as much as Immunocore ($8.8B against $1.6B).
ImmunityBio grew revenue faster over the last twelve months (193% versus 21.0% for Immunocore).
Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −599% at ImmunityBio.
ImmunityBio scores higher on the StockData Score (8 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IBRX | IMCR |
|---|---|---|
| Size and price | ||
| Market cap | $8.8B | $1.6B |
| Share price | $8.29 | $30.49 |
| Change, 1 year | 243% | −7.2% |
| Change, 5 years | −1.3% | −20.0% |
| Beta (5Y) | 1.61 | 0.70 |
| Employees | 691 | 524 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 3 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 53.0× | 3.6× (better) |
| P/B | – | 3.7× |
| FCF yield | −3.3% | −2.6% (better) |
| Fair value | – | $33.14 |
| Margin of safety | – | 8.0% |
| Growth | ||
| Revenue growth (TTM) | 193% (better) | 21.0% |
| Revenue growth, 5Y average | 185% | – |
| Profitability | ||
| Gross margin | 99.3% (better) | 98.9% |
| Operating margin | −152% | −5.2% (better) |
| Net margin | −599% | −4.2% (better) |
| FCF margin | −174% | −9.6% (better) |
| Return on equity | – | −4.5% |
| Financial health | ||
| Interest coverage | – | −1.8× |
| Current ratio | 5.72 (better) | 4.47 |
| Altman Z-score | −7.44 | 1.52 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 19.1% | 102% |
| Held by insiders | 75.3% | 15.5% |
| Insider net buying, 12 months | −$8.4M | −$5.6M (better) |
| Short interest, % of float | 47.3% | – |
Go deeper
- IBRX stock overview
- IBRX income statement
- IBRX valuation and score
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.